[
  {
    "ts": "2025-09-24T20:30:00+00:00",
    "headline": "Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
    "summary": "WILMINGTON, Del., September 24, 2025--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
    "url": "https://finance.yahoo.com/news/incyte-reports-inducement-grant-under-203000691.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "aa84027b-e7d9-34ea-b3ff-a0d9008884d2",
      "content": {
        "id": "aa84027b-e7d9-34ea-b3ff-a0d9008884d2",
        "contentType": "STORY",
        "title": "Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "description": "",
        "summary": "WILMINGTON, Del., September 24, 2025--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "pubDate": "2025-09-24T20:30:00Z",
        "displayTime": "2025-09-24T20:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/64a6bdc2b0acd0348edfe1f1cc271fd7",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2eXwgMWP0GeXt24oMIkQHQ--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/64a6bdc2b0acd0348edfe1f1cc271fd7.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SI6ZXTeR1zCK2OzFSW2g.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/64a6bdc2b0acd0348edfe1f1cc271fd7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-reports-inducement-grant-under-203000691.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-reports-inducement-grant-under-203000691.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T17:54:26+00:00",
    "headline": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
    "summary": "Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index shedding 0.2% and",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-175426612.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "400a75a9-1930-366c-af64-3e23e1f001e4",
      "content": {
        "id": "400a75a9-1930-366c-af64-3e23e1f001e4",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Softer Wednesday Afternoon",
        "description": "",
        "summary": "Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index shedding 0.2% and",
        "pubDate": "2025-09-24T17:54:26Z",
        "displayTime": "2025-09-24T17:54:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-175426612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-175426612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STAA"
            },
            {
              "symbol": "ALC.SW"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-24T05:58:02+00:00",
    "headline": "Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now. On September 17, Incyte announced new 24-week interim data from its pivotal Phase 3 STOP-HS clinical trial program for povorcitinib/INCB54707, which is an oral small-molecule, highly-selective JAK1 inhibitor, in adult patients with moderate to severe hidradenitis suppurativa/HS. The results support the company’s planned […]",
    "url": "https://finance.yahoo.com/news/incyte-povorcitinib-shows-sustained-efficacy-055802446.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2c7b6279-7441-30a4-8038-0ea55460cc80",
      "content": {
        "id": "2c7b6279-7441-30a4-8038-0ea55460cc80",
        "contentType": "STORY",
        "title": "Incyte’s Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions",
        "description": "",
        "summary": "Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now. On September 17, Incyte announced new 24-week interim data from its pivotal Phase 3 STOP-HS clinical trial program for povorcitinib/INCB54707, which is an oral small-molecule, highly-selective JAK1 inhibitor, in adult patients with moderate to severe hidradenitis suppurativa/HS. The results support the company’s planned […]",
        "pubDate": "2025-09-24T05:58:02Z",
        "displayTime": "2025-09-24T05:58:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Incyte's Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F08AN_WgfDoxxGlrVQfGRQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ux9OKsmqTigW_m7aYltcpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-povorcitinib-shows-sustained-efficacy-055802446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-povorcitinib-shows-sustained-efficacy-055802446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]